Clinical Trial

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2024 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
Efficacy and safety of MY008211A in IgAN patients
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-11.
Trial Details
NCT Number NCT06687174
Lead Sponsor Wuhan Createrna Science and Technology Co., Ltd
Conditions IgA Nephropathy (IgAN)
Enrollment 72 participants
Start Date 2024-12-31
Primary Completion 2026-06-15 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-18